Cubist was founded in 1992 and markets CUBICIN� (daptomycin for injection), the first IV antibiotic from a class of antibacterials called lipopeptides.  Our overall strategy is to discover, develop, and commercialize products that address unmet medical needs in the acute care environment.  This presentation will discuss recent data from two of our clinical pipeline compounds which are being evaluated for treatment of: Clostridium difficile-infection (CDI) (CB-183,315) as well as treatment of infections caused by multidrug resistant Gram negative bacteria (CXA-201). CB-183,315 was discovered internally at Cubist as an antibacterial drug candidate, and is a potent, oral, bactericidal lipopeptide.  CXA-201 is a novel cephalosporin/tazobactam combination product for the treatment of infections due to drug-resistant Pseudomonas aeruginosa and other Gram-negative pathogens.  Also presented will be our discovery pipeline strategy and this will include discussion of a recent X-ray co-crystal structure of a clinically important beta-lactamase.

Discovery of new antibacterial agents targeting gram-positive and gram-negative infections

243rd National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.